<DOC>
	<DOCNO>NCT03046069</DOCNO>
	<brief_summary>Three main class inhale treatment exist chronic obstructive pulmonary disease ( COPD ) : Beta2-adrenergic agonist ( may short ( SABA ) long ( LABA ) act ) , long-acting muscarinic acetylcholine receptor antagonist ( LAMA ) , inhaled corticosteroid ( ICS ) . For subject high risk exacerbation , treatment three class medication recommend . This study aim explore potential utility device call single inhaler triple combination fluticasone furoate/ umeclidinium/ vilanterol ( FF/UMEC/VI ) inhaler contain three group compound . This mixed method study qualitative phase quantitative Discrete Choice Experiment ( DCE ) phase conduct four stage : qualitative concept elicitation , DCE development , DCE pilot testing , conduct DCE . The study conduct United Kingdom ( UK ) , United States ( US ) Germany approximately 573 subject COPD include .</brief_summary>
	<brief_title>FF/UMEC/VI Inhaler : Qualitative Analysis Subject Preference Survey</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Diagnosis COPD , selfreported . Age : More equal 40 year . Moderate severe COPD , indicate COPD Assessment Test ( CAT ) score great equal 10 Modified Medical Research Council ( MMRC ) score great equal 2 . Currently prescribe receive one follow treatment type : ICS/LABA ; LABA/LAMA ; ICS/LABA/LAMA ( triple therapy ) ; LAMA . Currently resident UK , US Germany . Adequate write oral fluency language country residence . Willing able understand study provide inform consent . Has access internet ( Cognitive interview DCE survey ) . Has take part stage study . Subjects current diagnosis asthma . ( Subjects prior history asthma eligible current diagnosis COPD ) . Any comorbidity would inhibit ability provide inform consent allow participation telephone facetoface interview .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Triple therapy</keyword>
	<keyword>COPD</keyword>
	<keyword>DCE</keyword>
	<keyword>Qualitative</keyword>
</DOC>